BUZZ-Australia's ReNerve rises on Malaysian approval for its NervAlign product

Like
Comment
Favorite

BUZZ-Australia's ReNerve rises on Malaysian approval for its NervAlign product

Reuters01-15

BUZZ-Australia's ReNerve rises on Malaysian approval for its NervAlign product

** Shares of ReNerve RNV.AX rise as much as 30% to A$0.130, their highest levels since November 24

** Stock marks its biggest intraday pct gain since November 13

** The medical device innovator receives market registration approval in Malaysia for its NervAlign Nerve Cuff

** Adds that product is used in peripheral nerve repair, offering precise solution for supporting nerve regeneration

** Stock lost over 40% in 2025

(Reporting by Rajasik Mukherjee in Bengaluru)

((Rajasik.Mukherjee@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2603628087?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 07:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603628087","market":"fut","top_or_hot":-1,"title":"BUZZ-Australia's ReNerve rises on Malaysian approval for its NervAlign product","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's ReNerve rises on Malaysian approval for its NervAlign product </title></head><body><p>** Shares of ReNerve <span>RNV.AX</span> rise as much as 30% to A$0.130, their highest levels since November 24</p><p>** Stock marks its biggest intraday pct gain since November 13</p><p>** The medical device innovator receives market registration approval in Malaysia for its NervAlign Nerve Cuff</p><p>** Adds that product is used in peripheral nerve repair, offering precise solution for supporting nerve regeneration</p><p>** Stock lost over 40% in 2025</p><p> (Reporting by Rajasik Mukherjee in Bengaluru)</p><p> ((Rajasik.Mukherjee@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Australia's ReNerve rises on Malaysian approval for its NervAlign product</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Australia's ReNerve rises on Malaysian approval for its NervAlign product\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-15 07:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's ReNerve rises on Malaysian approval for its NervAlign product </title></head><body><p>** Shares of ReNerve <span>RNV.AX</span> rise as much as 30% to A$0.130, their highest levels since November 24</p><p>** Stock marks its biggest intraday pct gain since November 13</p><p>** The medical device innovator receives market registration approval in Malaysia for its NervAlign Nerve Cuff</p><p>** Adds that product is used in peripheral nerve repair, offering precise solution for supporting nerve regeneration</p><p>** Stock lost over 40% in 2025</p><p> (Reporting by Rajasik Mukherjee in Bengaluru)</p><p> ((Rajasik.Mukherjee@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7126","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nL4N3YF264:1","article_id":"2603628087","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603628087","pubTimestamp":1768435197,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Australia's ReNerve rises on Malaysian approval for its NervAlign product ** Shares of ReNerve RNV.AX rise as much as 30% to A$0.130, their highest levels since November 24** Stock marks its biggest intraday pct gain since November 13** The medical device innovator receives market registration approval in Malaysia for its NervAlign Nerve Cuff** Adds that product is used in peripheral nerve repair, offering precise solution for supporting nerve regeneration** Stock lost over 40% in 2025  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7126":"医疗保健用品","RNV.AU":"Renerve Ltd"},"translate_title":"BUZZ-澳大利亚ReNerve因马来西亚批准其NervAlign产品而股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNV.AU":0.9},"content_text":"BUZZ-Australia's ReNerve rises on Malaysian approval for its NervAlign product ** Shares of ReNerve RNV.AX rise as much as 30% to A$0.130, their highest levels since November 24** Stock marks its biggest intraday pct gain since November 13** The medical device innovator receives market registration approval in Malaysia for its NervAlign Nerve Cuff** Adds that product is used in peripheral nerve repair, offering precise solution for supporting nerve regeneration** Stock lost over 40% in 2025 (Reporting by Rajasik Mukherjee in Bengaluru) ((Rajasik.Mukherjee@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}